Table 3. Univariate analysis of DFS and OS for 218 EGFR mutated and 348 EGFR wild-type adenocarcinoma patients.

Variable	EGFR mutation					EGFR wild-type
	n	Median DFS (mo)	P-value	Median OS (mo)	P-value	n	Median DFS (mo)	P-value	Median OS (mo)	P-value
Total	218					348
Gender
Female	138	45	0.143	63.6	0.218	164	30.4	0.908	52.9	0.812
Male	80	35		56.9		184	36		52.9
Age (years)
≤ 60	132	36.5	0.356	60.6	0.18	178	30	0.849	52.7	0.979
> 60	86	47.8		66.7		170	36		59.8
Smoking history
Never	129	36.5	0.437	65.6	0.751	159	32.4	0.633	52.7	0.637
Former/current	89	44.4		56.9		189	31		52.9
Clinical Stage
I	120	46.5	< 0.001	NR	< 0.001	177	46.5	< 0.001	NR	< 0.001
II	30	37.2		53.8		54	30.4		59.8
IIIa	68	23.3		43.7		117	15.2		38.2
Tumor size
≤ 3 cm	135	47.6	0.067	64.6	0.028	211	36	0.22	59.8	0.774
> 3 cm	83	30		49.2		137	30.4		44.6
Regional lymph node metastasis
No	134	50.8	< 0.001	66.1	< 0.001	207	44.9	< 0.001	56	0.001
Yes	84	26.4		48.6		141	23		39.5
EGFR mutation subtype
Exon 19 deletion	105	44.6	0.704	62.9	0.362
L858R substitution	113	37.6		57.9
Surgical Resection
Pneumonectomy	6	12	0.101	35.5	0.216	36	21	0.315	33.5	0.426
Lobectomy	184	47.6		62.9		296	36		59.8
Wedge resection	28	36		51.7		16	24.3		39.5
Adjuvant treatment
Chemotherapy	120	44.4	< 0.001	60.6	0.001	236	35	< 0.001	59.8	< 0.001
Postoperative radiotherapy	6	12.2		32.5		2	11.2		11.2
Chemoradiotherapy	29	21.3		43.5		61	12.2		33.5
Others/none	63	50.8		66.5		49	49		58.4
CEA
≤ 5.0 ng/ml	132	46.4	< 0.001	NR	< 0.001	225	47.7	< 0.001	NR	< 0.001
> 5.0 ng/ml	86	25		48.6		123	15		33.5
Cyfra21–1
≤ 3.3 ng/ml	150	50.8	< 0.001	NR	< 0.001	235	37.5	0.001	54.7	0.001
> 3.3 ng/ml	68	24		42.6		113	23.3		39
SCCA
≤ 1.5 ng/ml	206	44.4	0.102	62.6	0.147	319	35	0.162	52.9	0.646
> 1.5 ng/ml	12	21.3		35.4		29	30.4		53.3
NSE
≤ 15.2 ng/ml	148	48.5	0.264	NR	0.216	263	30.9	0.833	52.9	0.425
> 15.2 ng/ml	70	35		55.8		85	36		39.5
Exon 19 deletion subgroup (n = 105)CEA
≤ 5.0 ng/ml	64	50.7	0.081	NR	0.071
> 5.0 ng/ml	41	34.1		50.5
Cyfra21–1
≤ 3.3 ng/ml	75	48.6	0.076	NR	0.001
> 3.3 ng/ml	30	34		48.6
NSE
≤ 15.2 ng/ml	68	37.2	0.849	59	0.958
> 15.2 ng/ml	37	45		60.6
L858R substitution subgroup (n = 113)CEA
≤ 5.0 ng/ml	68	52.9	< 0.001	NR	< 0.001
> 5.0 ng/ml	45	16.3		35.5
Cyfra21–1
≤ 3.3 ng/ml	75	60.9	0.002	63.4	0.001
> 3.3 ng/ml	38	16.3		35.5
NSE
≤ 15.2 ng/ml	80	51.8	0.061	57.9	0.07
> 15.2 ng/ml	33	26.4		51.7